Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ustekinumab for the Treatment of Refractory Crohnʼs Disease: The Spanish Experience in a Large Multicentre Open-label Cohort

Open access
Khorrami, Sam, Ginard, Daniel, Marín-Jiménez, Ignacio, Chaparro, María, Sierra, Mónica, Aguas, Mariam, Sicilia, Beatriz, García-Sánchez, Valle, Suarez, Cristina, Villoria, Albert, Taxonera, Carlos, Velasco-Guardado, Antonio, Martínez-González, Javier, Gisbert, Javier P. · 2016 · Inflammatory Bowel Diseases

Abstract

BACKGROUND: Ustekinumab is a fully human monoclonal antibody against IL-12/23. Ustekinumab induced clinical response and maintained higher rate of response than placebo in patients with Crohn's disease (CD). This study aims to assess the effectiveness and safety of ustekinumab in refractory patients with CD in real-life practice. METHODS: Consecutive patients with CD who were treated with subcutaneous ustekinumab between March 2010 and December 2014 were retrospectively included in a multicenter open-label study. Clinical response was defined by Harvey-Bradshaw index score and assessed after the loading doses, 6, 12 months, and last follow-up. RESULTS: One hundred sixteen patients were included, with a median follow-up of 10 months (interquartile range: 5-21). Clinical response after loading ustekinumab was achieved in 97/116 (84%) patients. The clinical benefit at 6, 12 months, and at the end of the follow-up was 76%, 64%, and 58%, respectively. Dose escalation was effective in 8 of 11 (73%) patients. Perianal disease also improved in 11 of 18 (61%) patients with active perianal fistulae. The initial response to ustekinumab and previous use of more than 2 immunosuppressant drugs were associated with a clinical response to ustekinumab maintenance therapy. In contrast, previous bowel resection predicted a long-term failure with ustekinumab. Adverse events were reported in 11 (9.5%) patients, but none required ustekinumab withdrawal. CONCLUSIONS: Subcutaneous ustekinumab is effective and safe in a high proportion of patients with CD that were resistant to conventional immunosuppressant and antitumor necrosis factor drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0000000000000842

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 166

Metadata

Authors
Khorrami, S., Ginard, D., Marín-Jiménez, I., Chaparro, M., Sierra, M., Aguas, M., Sicilia, B., García-Sánchez, V., Suarez, C., Villoria, A., Taxonera, C., Velasco-Guardado, A., Martínez-González, J., & Gisbert, J. P.
Venue
Inflammatory Bowel Diseases
Published
2016-07
Volume
22
Issue
7
Pages
1662-1669
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2424311920
Cited by
166
References
1
FWCI
16.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ustekinumab for the Treatment of Refractory Crohnʼs Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. https://app.cochat.ai/papers/10.1097/mib.0000000000000842
The paper
Khorrami, S., Ginard, D., Marín-Jiménez, I., Chaparro, M., Sierra, M., Aguas, M., Sicilia, B., García-Sánchez, V., Suarez, C., Villoria, A., Taxonera, C., Velasco-Guardado, A., Martínez-González, J., & Gisbert, J. P. (2016). Ustekinumab for the Treatment of Refractory Crohnʼs Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000842

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.